Patents by Inventor Roberto Biassoni

Roberto Biassoni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells and Antibodies That Identify the Same
    Publication number: 20100015153
    Abstract: The invention relates to a novel compound termed NKp30 that is selectively expressed by all mature NK cells and that is involved in human natural cytoxicity as an activatory receptor, to new antibodies that bind to the NKp30 structure, and to the pharmaceutical and medicinal uses thereof.
    Type: Application
    Filed: February 25, 2009
    Publication date: January 21, 2010
    Applicants: Innate Pharma, S.A., Universita Di Genova
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
  • Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same
    Patent number: 7517966
    Abstract: The invention relates to a novel compound termed NKp30 that is selectively expressed by all mature NK cells and that is involved in human natural cytoxicity as an activatory receptor, to new antibodies that bind to the NKp30 structure, and to the pharmaceutical and medicinal uses thereof.
    Type: Grant
    Filed: May 25, 2005
    Date of Patent: April 14, 2009
    Assignees: Innate Pharma S.A.S., Universita Di Genova
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
  • POLYPEPTIDES HAVING A TRIGGERING NK ACTIVITY AND BIOLOGICAL APPLICATIONS
    Publication number: 20080248045
    Abstract: The invention relates to polypeptides having a triggering NK activity and an amino acid sequence that is at least 80% identical over its entire length to the polypeptide having SEQ ID NO: 1, and any immunogenic fragments thereof, as well as to the polyclonal and monoclonal antibodies directed against said polypeptides, and immuno-reactive fragments thereof. Application for detecting NK cells in a sample, for their removal from a sample or for enrichment of NK cells, and for NK cell natural cytotoxicity regulation.
    Type: Application
    Filed: September 26, 2007
    Publication date: October 9, 2008
    Applicants: Innate Pharma, S.A., Universita di Genova
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
  • Methods of diagnosis and treatment by binding p75/AIRM1
    Patent number: 7384631
    Abstract: p75/AIRM1 is expressed on myeloid cells at stages of differentiation and determination of its presence is useful in monitoring cellular proliferation and determining proliferative states of cells, especially myeloid cells in diseases such as chronic myeloid leukemia. Ligands such as antibody molecules, for instance the QA79 monoclonal antibody deposited under accession number ICLC No. PD99003, are useful for methods of diagnosis and treatment, e.g. by way of inhibition of cellular proliferation and induction of apoptosis in cells.
    Type: Grant
    Filed: December 11, 2000
    Date of Patent: June 10, 2008
    Assignee: Universita Degli Studi Di Genova, Dipartimento Di Medicina Sperimentale
    Inventors: Roberto Biassoni, Alessandro Moretta, Lorenzo Moretta, Maria Cristina Mingari
  • Polypeptides having a triggering NK activity and biological applications
    Patent number: 7279291
    Abstract: The invention relates to polypeptides having a triggering NK activity and an amino acid sequence that is at least 80% identical over its entire length to the polypeptide having SEQ ID NO: 1, and any immunogenic fragments thereof, as well as to the polyclonal and monoclonal antibodies directed against said polypeptides, and immuno-reactive fragments thereof. Application for detecting NK cells in a sample, for their removal from a sample or for enrichment of NK cells, and for NK cell natural cytotoxicity regulation.
    Type: Grant
    Filed: July 10, 2006
    Date of Patent: October 9, 2007
    Assignees: Innate Pharma, S.A., Universita Di Genova
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
  • NTB-A, a surface molecule involved in natural killer cells activity
    Publication number: 20070065875
    Abstract: The present invention relates to a novel protein, termed NTB-A, nucleic acid molecules encoding the same and uses thereof. The invention also relates to methods of regulating Natural Killer cells activity by regulating the activity of NTB-A in vitro, ex vivo or in vivo. The invention also comprises methods of screening active compounds using NTB-A or fragments thereof, or nucleic acid encoding the same, or recombinant host cells expressing said polypeptide.
    Type: Application
    Filed: November 16, 2006
    Publication date: March 22, 2007
    Applicants: Innate Pharma, S.A., Universita Di Genova
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
  • NTB-A, a surface molecule involved in natural killer cells activity
    Patent number: 7138243
    Abstract: The present invention relates to a novel protein, termed NTB-A, nucleic acid molecules encoding the same and uses thereof. The invention also relates to methods of regulating Natural Killer cells activity by regulating the activity of NTBA-A in vitro, ex vivo or in vivo. The invention also comprises methods of screening active compounds using NTB-A or fragments thereof, or nucleic acid encoding the same, or recombinant host cells expressing said polypeptide.
    Type: Grant
    Filed: July 17, 2002
    Date of Patent: November 21, 2006
    Assignees: Innate Pharma, S.A., University of Genova
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
  • Polypeptides having a triggering NK activity and biological applications
    Publication number: 20060246068
    Abstract: The invention relates to polypeptides having a triggering NK activity and an aminoacid sequence that is at least 80% identical over its entire length to the polypeptide having SEQ ID NO: 1, and any immunogenic fragments thereof, as well as to the polyclonal and monoclonal antibodies directed against said polypeptides, and immuno-reactive fragments thereof. Application for detecting NK cells in a sample, for their removal from a sample or for enrichment of NK cells, and for NK cell natural cytotoxicity regulation.
    Type: Application
    Filed: July 10, 2006
    Publication date: November 2, 2006
    Applicants: Innate Pharma, Universita di Genova
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
  • Polypeptides having a triggering NK activity and biological applications
    Patent number: 7074409
    Abstract: The invention relates to polypeptides having a triggering NK activity and an aminoacid sequence that is at least 80% identical over its entire length to the polypeptide having SEQID N°1, and any immunogenic fragments thereof, as well as to the polyclonal and monoclonal antibodies directed against said polypeptides, and immuno-reactive fragments thereof. Application for detecting NK cells in a sample, for their removal from a sample or for enrichment of NK cells, and for NK cell natural cytotoxicity regulation.
    Type: Grant
    Filed: December 27, 2001
    Date of Patent: July 11, 2006
    Assignees: Innate Pharma, Universita di Genova
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
  • Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same
    Patent number: 6979546
    Abstract: The invention relates to a novel compound termed NKp30 that is selectively expressed by all mature NK cells and that is involved in human natural cytoxicity as an activatory receptor, to new antibodies that bind to the NKp30 structure, and to the pharmaceutical and medicinal uses thereof.
    Type: Grant
    Filed: January 7, 2002
    Date of Patent: December 27, 2005
    Assignees: Universita di Genova, Innate Pharma S.A.S.
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
  • Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same
    Publication number: 20050221438
    Abstract: The invention relates to a novel compound termed NKp30 that is selectively expressed by all mature NK cells and that is involved in human natural cytoxicity as an activatory receptor, to new antibodies that bind to the NKp30 structure, and to the pharmaceutical and medicinal uses thereof.
    Type: Application
    Filed: May 25, 2005
    Publication date: October 6, 2005
    Applicants: Innate Pharma, Universita Di Genova
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
  • Ntb-a,a a surface molecule involved in natural killer cellss activity
    Publication number: 20050159332
    Abstract: The present invention relates to a novel protein, termed NTB-A, nucleic acid molecules encoding the same and uses thereof. The invention also relates to methods of regulating Natural Killer cells activity by regulating the activity of NTBA-A in vitro, ex vivo or in vivo. The invention also comprises methods of screening active compounds using NTB-A or fragments thereof, or nucleic acid encoding the same, or recombinant host cells expressing said polypeptide.
    Type: Application
    Filed: July 17, 2002
    Publication date: July 21, 2005
    Applicants: Innate Pharma, Universita Di Genova
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
  • Polypeptides having a triggering nk activity and biological applications
    Publication number: 20040115738
    Abstract: The invention relates to polypeptides having a triggering NK activity and an aminoacid sequence that is at least 80% identical over its entire length to the polypeptide having SEQ ID NO 1, and any immunogenic fragments thereof, as well as to the polyclonal and monoclonal antibodies directed against said polypeptides, and immuno-reactive fragments thereof. Application for detecting NK cells in a sample, for their removal from a sample or for enrichment of NK cells, and for NK cell natural cytotoxicity regulation.
    Type: Application
    Filed: August 27, 2003
    Publication date: June 17, 2004
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
  • Methods of diagnosis and treatment by binding p75/airm1
    Publication number: 20030077285
    Abstract: p75/AIRM1 is expressed on myeloid cells at stages of differentiation and determination of its presence is useful in monitoring cellular proliferation and determining proliferative states of cells, especially myeloid cells in diseases such as chronic myeloid leukemia. Ligands such as antibody molecules, for instance the QA79 monoclonal antibody deposited under accession number ICLC No. PD99003, are useful for methods of diagnosis and treatment, e.g. by way of inhibition of cellular proliferation and induction of apoptosis in cells.
    Type: Application
    Filed: October 2, 2002
    Publication date: April 24, 2003
    Inventors: Roberto Biassoni, Alessandro Moretta, Lorenzo Moretta, Maria Cristina Mingari
  • Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same
    Publication number: 20020142445
    Abstract: The invention relates to a novel compound termed NKp30 that is selectively expressed by all mature NK cells and that is involved in human natural cytotoxicity as an activatory receptor, to new antibodies that bind to the NKp30 structure, and to the pharmaceutical and medicinal uses thereof.
    Type: Application
    Filed: January 7, 2002
    Publication date: October 3, 2002
    Applicant: Universita di Genova
    Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni